Motley Fool Asset Management LLC bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 1,721 shares of the company’s stock, valued at approximately $206,000. A number of other hedge funds also recently made changes […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) – Equities researchers at HC Wainwright decreased their Q2 2023 EPS estimates for Neurocrine Biosciences in a report released on Thursday, May 4th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of $0.76 per share for the quarter, down from their prior estimate […]
Guggenheim upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) from a neutral rating to a buy rating in a research note released on Thursday, The Fly reports. The brokerage currently has $145.00 price target on the stock. Several other equities research analysts have also issued reports on NBIX. Canaccord Genuity Group raised shares of […]
Guggenheim upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) from a neutral rating to a buy rating in a research report released on Thursday morning, The Fly reports. They currently have $145.00 target price on the stock. Other equities analysts have also recently issued reports about the company. Citigroup reduced their target price on […]
Fiera Capital Corp reduced its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 0.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 372,519 shares of the company’s stock after selling 2,568 shares during the quarter. Fiera Capital Corp […]